Form 4: Illumina SVP, Chief People Officer Patricia Leckman Reports Acquisition and Disposal of Shares

Patricia Leckman, SVP, Chief People Officer of Illumina, Inc., reports the acquisition of restricted stock units and performance shares, as well as the disposal of common stock.

Summary

• On March 5, 2024, Patricia Leckman, SVP, Chief People Officer of Illumina, Inc., reported transactions involving the company's stock.
• Leckman acquired 7,054 shares of common stock and disposed of 15,792 shares.
• Additionally, she acquired 5,755 performance shares tied to the company's three-year average operating margin for fiscal years 2024-2026, vesting on January 3, 2027.
• She also acquired 5,755 performance shares linked to the company's relative total shareholder return for the fiscal year ending January 3, 2027, also vesting on January 3, 2027.
• The number of shares issued for both performance share grants will range from 0% to 200% of the specified amount, based on the company's performance against pre-defined objectives.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The acquisition of performance shares aligns the executive's interests with the company's long-term performance, specifically related to operating margin and shareholder return.

Risks

• The value of the performance shares is contingent on Illumina achieving specific financial targets, and there is a risk that these targets may not be met, resulting in a lower payout.

Future Outlook

The number of shares issued for the performance stock units will range from 0% to 200% of the amount specified, based on the company's actual three-year average operating margin for fiscal years 2024-2026 and the company's relative total shareholder return for the fiscal year ending January 3, 2027, relative to pre-defined objectives.

Industry Context

Executive stock transactions are common in publicly traded companies and are closely monitored by investors for insights into management's confidence in the company's future prospects.

Comparison to Industry Standards

• Performance-based equity compensation is a standard practice among publicly traded companies, particularly in the technology and biotechnology sectors, to align executive compensation with shareholder value creation.
• Companies like Thermo Fisher Scientific and Danaher also utilize performance-based equity awards tied to metrics such as revenue growth, operating income, and total shareholder return.
• The vesting schedules and performance metrics used by Illumina appear to be in line with industry norms.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into executive compensation and alignment with company performance.

Key Dates